WINTER PARK, FL, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (Ticker: IMUN) announced today that Cytocom, Inc., a company that spun-off from Immune in 2014, is participating in Biotech Showcase Digital and H.C. Wainwright BioConnect. Both events will be held virtually and are scheduled alongside the J.P. Morgan 39th Annual Healthcare Conference 2021.
See the original post:
Immune Therapeutics Inc. Spinoff Cytocom, Inc. to Participate in Biotech Showcase and H.C. Wainwright BioConnect 2021 During “J.P. Morgan Week...
Related Post
- Talis Biomedical Announces First Quarter 2021 Financial Results and Business Progress - May 12th, 2021
- Opiant Pharmaceuticals Announces First Quarter 2021 Financial Results and Corporate Update - May 12th, 2021
- Baudax Bio Announces Partial Adjournment of Annual Meeting of Shareholders - May 12th, 2021
- Yield10 Bioscience Announces First Quarter 2021 Financial Results - May 12th, 2021
- Kronos Bio Reports Recent Business Progress and First Quarter Financial Results and Announces Virtual R&D Day - May 12th, 2021
- Novan Reports First Quarter 2021 Financial Results and Provides Corporate Update - May 12th, 2021
- GENFIT Provides Pipeline Update and Launch of New Clinical Programs - May 12th, 2021
- Vaxcyte Reports First Quarter 2021 Financial Results and Provides Business Update - May 12th, 2021
- ARCA biopharma Announces First Quarter 2021 Financial Results and Provides Corporate Update - May 12th, 2021
- Otonomy Reports First Quarter 2021 Financial Results and Provides Corporate Update - May 12th, 2021
- Cellectis and Sanofi partner on alemtuzumab as lymphodepletion agent for allogeneic CAR-T - May 12th, 2021
- Aileron Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update - May 12th, 2021
- InflaRx Announces Positive Topline Results for Vilobelimab from the U.S. Phase II ANCA-Associated Vasculitis IXPLORE Study - May 12th, 2021
- BIOPHYTIS Completed Recruitment of 155 Participants to the COVA Phase 2-3 Study with Sarconeos (BIO101) in COVID-19 allowing the 2nd Interim Analysis - May 12th, 2021
- Innate Pharma Virtual 2021 Annual General Meeting - May 12th, 2021
- Timber Pharmaceuticals Provides Business Update and Announces First Quarter 2021 Financial Results - May 12th, 2021
- Preliminary results for the year ended 31 December 2020 - May 12th, 2021
- Antion Biosciences Presents New Data on miCARTM T-cells and Multiplex Gene Engineering Technology at American Society of Gene & Cell Therapy... - May 12th, 2021
- Indigo Diabetes Appoints Paul Moraviec as Chairman of the Board - May 12th, 2021
- Burning Rock to be Added to MSCI China Index - May 12th, 2021
- Immutep Operational Update - May 9th, 2021
- Ocuphire Announces Financial Results for the First Quarter 2021 and Provides Corporate Update - May 9th, 2021
- Medicenna Announces the Peer-Reviewed Publication of Clinical Data from Phase 2b Trial Evaluating MDNA55 in Recurrent Glioblastoma - May 9th, 2021
- Celsion Corporation to Hold First Quarter 2021 Financial Results and Business Update Conference Call on Friday, May 14, 2021 - May 9th, 2021
- Vallon Pharmaceuticals to Present at the Q2 Virtual Investor Summit - May 9th, 2021
- Ensysce Biosciences’ Covistat Subsidiary “At Home Coronavirus Pill” Commencing to Phase 2 clinical development - May 9th, 2021
- Palisade Bio and Newsoara Announce Completion of Phase 2 Study in GI Surgery Study in China - May 9th, 2021
- Auris Medical Provides Update on Bentrio Program in Allergy - May 9th, 2021
- ORYZON Reports Results and Corporate Update for Quarter Ended March 31, 2021 - May 9th, 2021
- New and Potentially Revolutionary HOCL Product Receives Halal Certification - May 9th, 2021
- Rafarma To Expand Proton Therapy Centers - May 9th, 2021
- Raymond James Welcomes Technology Industry Veteran to New Role Supporting RIA & Custody Services Division - May 9th, 2021
- VALNEVA : Déclaration d’actions et de droits de vote – Avril 2021 - May 9th, 2021
- Monthly information related to total number of voting rights and shares composing the share capital – April 30, 2021 - May 9th, 2021
- Coherus BioSciences to Present at the Bank of America Health Care Conference - May 9th, 2021
- Trading in Novo Nordisk shares by board members, executives and associated persons on 7 May 2021 - May 9th, 2021
- Cocrystal Pharma Announces Closing of $40 Million Bought Deal - May 9th, 2021
- Amphastar Announces Buyback of 26% of the Equity in its ANP Subsidiary and Spin-off its Hanxin Subsidiary - May 9th, 2021
- Osmotica Pharmaceuticals plc to Provide First Quarter 2021 Business and Financial Update on May 13, 2021 - May 9th, 2021
- Avicanna Announces Resignation of Board Member - May 9th, 2021
- Annual General Meeting of April 30, 2021 - May 2nd, 2021
- Santhera Completes Capital Increases for Financing Arrangements - May 2nd, 2021
- 22nd Century Group Welcomes Ban on Menthol Cigarettes and Anticipates Further Standards as FDA Commissioner Reports Nicotine Cap on Combustibles... - May 2nd, 2021
- Agile Therapeutics Announces Presentation of Safety and Efficacy Data of Twirla® (Levonorgestrel and Ethinyl Estradiol) Transdermal System in Women... - May 2nd, 2021
- Galapagos creates new subscription right plans - May 2nd, 2021
- PCI Biotech: First US patient enrolled in the fimaChem pivotal RELEASE study - May 2nd, 2021
- AB Science reports today its annual financials as of 31 December 2020 and provides an update on its activities - May 2nd, 2021
- ObsEva SA presents posters at the ACOG Annual Clinical and Scientific Virtual Meeting April 30 - May 2, 2021 - May 2nd, 2021
- Progenity Presents Key Verification Study Data for Preecludia™ Preeclampsia Rule-out Test at the 2021 American College of Obstetricians and... - May 2nd, 2021
- Blueberries Medical Reports 2020 Financial Results - May 2nd, 2021
- AnPac Bio Announces Filing of Annual Report on Form 20-F for 2020 - May 2nd, 2021
- ECMOHO Announces Fourth Quarter Unaudited Financial Results and Fiscal Year 2020 Audited Financial Results - May 2nd, 2021
- Eve & Co Announces Financial Results for the Year Ended December 31, 2020 - May 2nd, 2021
- Shattuck Labs Announces Participation in Upcoming May Conferences - May 2nd, 2021
- Gracell Biotechnologies to Participate in Upcoming Virtual Conferences in May - May 2nd, 2021
- Oyster Point Pharma Announces Clinical Data Presentation of OC-01 (varenicline) Nasal Spray for Dry Eye Disease at the Association for Research in... - May 2nd, 2021
- Editas Medicine to Present Preclinical Data Demonstrating Advancements in In Vivo Gene Editing Approach for the Treatment of Genetic Ocular Diseases... - May 2nd, 2021
- Novartis Phase III Beovu® data show potential for fluid resolution in more diabetic macular edema patients with fewer injections versus aflibercept - May 2nd, 2021
- Adverum Biotechnologies Presents Long-term Data through March 10, 2021 from the OPTIC Trial of ADVM-022 Intravitreal Gene Therapy in... - May 2nd, 2021
- Denali Therapeutics Presents Positive Results from Phase 1 and Phase 1b Studies of Its LRRK2 Inhibitor, BIIB122/DNL151, Supporting Late-Stage... - May 2nd, 2021
- Orphazyme to present at upcoming investor conferences - April 28th, 2021
- Sigilon Therapeutics Announces Presentations at the American Society of Gene and Cell Therapy 24th Annual Meeting - April 28th, 2021
- Affinia Therapeutics to Present New Data and Updates on AAV Platform at the American Society of Gene and Cell Therapy Annual Meeting - April 28th, 2021
- Pacific Biosciences Nominates Dr. Hannah Valantine to its Board of Directors - April 28th, 2021
- Travere Therapeutics to Present at the BofA Securities 2021 Virtual Health Care Conference - April 28th, 2021
- Adaptimmune to Present First Preclinical Data from its HLA-independent TCR (HiT) Platform at ASGCT - April 28th, 2021
- Codiak to Present Preclinical Data Demonstrating Broad Potential Applications for Engineered Exosomes at the American Society for Gene and Cell... - April 28th, 2021
- New Preclinical Data from Dyne Therapeutics’ Myotonic Dystrophy Type 1 Program to be Featured in Presentations During Upcoming American Society of... - April 28th, 2021
- Freeline to Present Data at the American Society of Gene and Cell Therapy Annual Meeting 2021 - April 28th, 2021
- 4D Molecular Therapeutics Announces Preclinical Data Presentations at ASGCT and ATS Annual Meetings on Three Wholly-Owned Product Candidates from... - April 28th, 2021
- Akouos to Present Nonclinical Data from AK-OTOF and AK-antiVEGF Programs at the American Society of Gene and Cell Therapy 24th Annual Meeting - April 28th, 2021
- Generation Bio to Present at American Society of Gene & Cell Therapy 2021 Virtual Annual Meeting - April 28th, 2021
- Krystal Biotech Announces Virtual Presentation of Data from its Vector-Encoded-Antibody Platform at ASGCT - April 28th, 2021
- Intellia Therapeutics Announces Presentations at the 24th American Society of Gene and Cell Therapy Annual Meeting - April 28th, 2021
- Supernus to Host First Quarter 2021 Financial Results Conference Call - April 28th, 2021
- COMPASS Pathways launches proposed public offering - April 28th, 2021
- AnPac Bio to Report Fiscal Year 2020 Financial Results on Friday, April 30, 2021 - April 28th, 2021
- Sana Biotechnology to Present Pre-Clinical Data at American Society of Gene & Cell Therapy Annual Meeting 2021 - April 28th, 2021
- CMS Proposes Additional Payment for Shockwave’s Coronary IVL in Hospital Inpatient Cases - April 28th, 2021
- US FDA Advisory Committee votes in favour of maintaining accelerated approval of Roche’s Tecentriq for PD-L1-positive, metastatic triple-negative... - April 28th, 2021
Recent Comments